Market revenue in 2023 | USD 266.8 million |
Market revenue in 2030 | USD 765.5 million |
Growth rate | 16.3% (CAGR from 2023 to 2030) |
Largest segment | Dogs |
Fastest growing segment | Dogs |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Dogs |
Key market players worldwide | Zoetis Inc Class A, Merck & Co Inc, Elanco Animal Health Inc, Virbac SA, Boehringer Ingelheim, Indian Immunologicals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to monoclonal antibodies in veterinary health market will help companies and investors design strategic landscapes.
Dogs was the largest segment with a revenue share of 69.04% in 2023. Horizon Databook has segmented the Europe monoclonal antibodies in veterinary health market based on dogs covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe monoclonal antibodies in veterinary health market , including forecasts for subscribers. This continent databook contains high-level insights into Europe monoclonal antibodies in veterinary health market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account